Parametrica Management Ltd bought a new position in Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) during the second quarter, Holdings Channel reports. The fund bought 10,035 shares of the company’s stock, valued at approximately $338,000.

Several other institutional investors also recently modified their holdings of the company. Nuveen Asset Management LLC boosted its position in shares of Pacira Pharmaceuticals by 67.3% in the first quarter. Nuveen Asset Management LLC now owns 179,063 shares of the company’s stock worth $9,487,000 after buying an additional 72,034 shares during the last quarter. Opus Point Partners Management LLC boosted its position in shares of Pacira Pharmaceuticals by 83.7% in the first quarter. Opus Point Partners Management LLC now owns 35,110 shares of the company’s stock worth $1,860,000 after buying an additional 16,000 shares during the last quarter. Granahan Investment Management Inc. MA boosted its position in shares of Pacira Pharmaceuticals by 75.3% in the first quarter. Granahan Investment Management Inc. MA now owns 159,000 shares of the company’s stock worth $8,424,000 after buying an additional 68,300 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Pacira Pharmaceuticals by 5.4% in the first quarter. Geode Capital Management LLC now owns 262,536 shares of the company’s stock worth $13,909,000 after buying an additional 13,435 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Pacira Pharmaceuticals by 4.4% in the first quarter. State Street Corp now owns 1,109,611 shares of the company’s stock worth $58,792,000 after buying an additional 47,096 shares during the last quarter.

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) traded up 4.42% on Friday, hitting $42.33. The stock had a trading volume of 1,055,901 shares. Pacira Pharmaceuticals Inc. has a 12-month low of $31.08 and a 12-month high of $80.25. The company has a 50 day moving average of $41.07 and a 200 day moving average of $45.86. The company’s market capitalization is $1.58 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.03 by $0.16. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. The business earned $69.60 million during the quarter, compared to the consensus estimate of $67.80 million. During the same period in the previous year, the business earned $0.20 earnings per share. The company’s revenue was up 17.8% on a year-over-year basis. On average, equities analysts expect that Pacira Pharmaceuticals Inc. will post $0.42 earnings per share for the current year.

PCRX has been the topic of a number of research analyst reports. Wedbush decreased their price target on Pacira Pharmaceuticals from $113.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 25th. Zacks Investment Research upgraded Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price target on the stock in a research report on Wednesday, August 10th. Brean Capital restated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, August 5th. Mizuho restated a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Thursday, May 26th. Finally, BMO Capital Markets restated a “sell” rating and set a $36.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $73.64.

In other Pacira Pharmaceuticals news, President James S. Scibetta sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $45.21, for a total transaction of $1,130,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David M. Stack sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $45.32, for a total transaction of $679,800.00. The disclosure for this sale can be found here. Company insiders own 6.90% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc. (NASDAQ:PCRX).

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.